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SCP2 MUTATIONS AND NEURODEGENERATION
WITH BRAIN IRON ACCUMULATION
Mutations in PANK2, PLA2G6, C19orf12, FA2H,
ATP13A2,WDR45, COASY, FTL, CP, andDCAF17
cause neurodegeneration with brain iron accumula-
tion (NBIA), but the genetic etiology remains unde-
fined in many patients. We report the second patient
with sterol carrier protein x (SCPx) deficiency pre-
senting with adult-onset spinocerebellar ataxia and
brain MRI characteristic of NBIA.
Case report. A 51-year-old man developed hand
clumsiness in his 30s, followed by gait disturbance
and deafness. He was the first child of healthy,
nonconsanguineous parents with no relevant family
history. On examination, he had normal cognition,
speech, vision, and optic fundi. He had slow ocular
saccades but no nystagmus or ophthalmoparesis.
Lower cranial nerve examination was normal. There
was no muscle wasting or weakness, but tone was
increased with brisk deep tendon reflexes throughout.
Plantar responses were normal. Proprioception was
impaired. He had mild dysmetria, dysdiadochokinesis,
and a wide-based gait. There were no extrapyramidal
signs.
Routine biochemical analyses showed increased ala-
nine transaminase (88 U/L, normal,40), gamma glu-
tamyl transferase (78 U/L, normal,70), a-fetoprotein
(63 kU/L, normal ,10), creatine kinase (777 U/L,
normal ,40–320), and ferritin (539 mg/L, normal
,300 in men). Copper and ceruloplasmin were nor-
mal, as was the blood count, vitamin B12, and folate.
Free carnitine (65 mmol/L, normal ,52) and total
carnitine (85.6 mmol/L, normal ,63) were increased,
and there was a nonspecific increase in long chain
hydroxylacylcarnitines. Electrophysiology showed no
evidence of polyneuropathy.
3T MRI brain revealed abnormal T2 signal (figure,
A–E). Susceptibility-weighted sequences suggested
increased mineral deposition in the basal ganglia (fig-
ure, F–H). Spine imaging showed no significant
abnormality. Genetic testing for SCA1, SCA2, SCA3,
SCA6, SCA7, SCA17, DRPLA, FA, FTL, and HFE/p.
Cys282Tyr was negative.
Illumina TruSeq 62 Mb exome capture, sequenc-
ing (100 bp paired-end reads, HiSeq 2000), and
alignment (UCSC hg19) was performed. Variants
with a minor allele frequency .0.01 in local and
international databases were filtered out. Potentially
deleterious recessive variants were identified using
QIAGEN Ingenuity Variant Analysis, and validated
by Sanger sequencing (ABI 3130XL, Life Technolo-
gies, Carlsbad, CA), also used for the segregation
analysis. Immunoblotting was performed on 12.5
mg protein using standard protocols.
Results. No pathogenic mutations were identified in
genes known to cause NBIA despite 92% of bases being
covered .20-fold. Potentially pathogenic mutations
were identified in SCP2 (c.349C.T/p.Gln117*
c.121G.T/p.Glu41* figure, I), both predicted to
introduce premature stop codons and truncate SCPx.
Segregation analysis (unaffected mother and sister)
confirmed that the patient was a compound
heterozygote. Immunoblotting showed undetectable
levels of the SCPx protein in fibroblasts (figure, J).
Very long chain fatty acid analysis revealed high
pristanic acid (34.1 mmol/L, normal range 0–1.5)
and mildly increased phytanic acid (13.8 mmol/L,
normal ,11.5). Free carnitine (65 mmol/L, normal
,52) and total carnitine (85.6 mmol/L, normal
,63) were increased.
Discussion. The SCP2 mutations are likely to be
pathogenic because (1) c.349C.T has only been
described in heterozygotes in ,1/10,000 healthy
controls, and c.121G.T has never been previously
reported; (2) the predicted functional consequences
of the nonsense mutations were confirmed on West-
ern blot, with no detectable SCPx protein likely due
to nonsense-mediated decay of truncated transcripts;
(3) serum branched-chain pristanic and phytanic acid
levels were increased consistent with the biochemical
consequences of SCPx deficiency1; and (4) the only
other patient described with SCPx deficiency
presented was similar to the patient we describe here.1
Although our patient does not have a leukodystrophy at
present, there was striking thalamic and pontine T2
hypointensity as in the previous case (figure).1
SCPx is a peroxisomal enzyme with thiolase activity
required for the breakdown of branched chain fatty acids
(figure, K), and the pathogenic effects are likely to be
mediated by the accumulation of branch chain fatty acids,
as in other peroxisomal disorders.2 Mice with SCPx defi-
ciency develop normally, but develop ataxia and
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peripheral neuropathy when fed phytanic acid.3 After 2
months on a Refsum diet, our patient reported an
improvement of his symptoms, pristanic acid (14.0
mmol/L) and phytanic acid (2.5 mmol/L) levels were
reduced, and acyl-carnitines were within the normal
range, but the examination findings are unchanged so far.
Our patient had abnormal fatty-acid acyl-CoA
metabolism, which has emerged as a common disease
mechanism in NBIA (PANK2,4 FA2H,5,6 COASY11).
FA2H mutations cause a wide spectrum of pheno-
types encompassing the ataxia and spastic paraplegia,
and overt brain iron accumulation is not always
Figure Brain MRI and molecular and biochemical findings in the patient
(A–E) T2-weighted imaging shows signal change in the (A) subcortical white matter, (B) thalamus, (C) globus pallidus, (D)
cerebral peduncles, and (E) pons. (F–H) Susceptibility-weighted imaging shows signal dropout in the globus pallidus, sub-
stantia nigra, red nuclei, and dentate nuclei. (I) Confirmatory Sanger sequencing shows heterozygous mutations in SCP2. (J)
Western blot shows no detectable levels of steroid carrier protein x (SCPx) in fibroblasts from the patient using 12.5 mg
protein and monoclonal antibodies against SCPx and b-actin as a loading control. (K) Schematic representation of the
localization of the enzyme defect and the biochemical pathways affected by the mutations in SCP2. CoA 5 coenzyme A;
FA 5 fatty acid; VLCFA 5 very long-chain fatty acids.
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apparent on T2 brain imaging, even in severely
affected cases.7 This suggests that the brain iron accu-
mulation is secondary to the underlying metabolic
defect for FA2H and SCP2 patients, questioning
the role of iron chelation as a treatment in all forms
of NBIA.
The findings we report broaden the neurometa-
bolic basis to include peroxisomal disorders, and
point towards other potential treatments.
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